-
Uncategorized21 hours ago
Takeda ends partnership with Denali amid restructuring
Takeda’s ongoing restructuring has hit another Denali program as an eight-year-old partnership comes to an end between the two companies. Takeda returned the full rights to...
-
Uncategorized22 hours agoSTAT+: Pharmalittle: We’re reading about an FDA delay forcing a biotech to close, a Neurocrine deal, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating because that oh-too-familiar routine of meetings, deadlines, and...
-
Uncategorized23 hours ago
Pharma Pipeline Stalls for First Time in Decades: Citeline
Some disease areas bucked the trend of shrinking pipelines, however, with immune and cardiovascular indications seeing an upward trend in investigational assets.
-
Uncategorized23 hours agoNuclera launches GPCR-focused nanodisc panel
Nuclera has announced the launched of a nanodisc panel focused on supporting G-Protein Coupled Receptors (GPCR) research and streamlining membrane protein production. Building on the eProtein Discovery membrane protein workflow capabilities,...
-
Uncategorized23 hours agoNanotube Injector Boosts Mitochondrial Performance Through Cytoplasmic Transfer
Extracting cytoplasmic material such as proteins, RNA, and mitochondria often relies on cell lysis using detergents or enzymes, which destroy the cells. Ultrasound and other sophisticated...
-
Uncategorized23 hours agoSTAT+: Neurocrine Biosciences to buy Soleno Therapeutics in $2.9B deal
Neurocrine Biosciences said Monday that it would buy Soleno Therapeutics and its treatment for Prader-Willi syndrome for $2.9 billion. Neurocrine is paying $53 a share for...
-
Uncategorized24 hours ago
Neurocrine will pay $2.9B for Soleno and its Prader-Willi medicine
Neurocrine Biosciences is joining the M&A bonanza with a $2.9 billion takeover of profitable rare disease drugmaker Soleno Therapeutics. Neurocrine will pay $53 per share, a...
-
Uncategorized1 day ago
Stipple Bio launches with $100M to find more precise targets on cancer proteins
It’s no secret that cancer drug development is full of bandwagons. Companies see a promising target, and crowd around it (see PD-1xVEGF or HER2 for recent...
-
Uncategorized1 day ago
Perks persuade participants
The right incentive program can boost clinical trial enrollment and engagement. Read More
-
Uncategorized1 day agoOpinion: ‘Medical nutrition’ helps keep my son, and many others, healthy. But insurance won’t cover it
My son is now in high school, but when he was in the second grade, I received a call that changed everything: “We think he had...